PharmaEssentia Corporation (LUX: 261280523)
Luxembourg
· Delayed Price · Currency is EUR · Price in USD18.20
-0.90 (-4.71%)
At close: Nov 15, 2024
PharmaEssentia Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 8,320 | 5,106 | 2,882 | 656.51 | 557.26 | 305.69 | Upgrade
|
| Revenue Growth (YoY) | 93.47% | 77.15% | 339.00% | 17.81% | 82.29% | 1065.16% | Upgrade
|
| Cost of Revenue | 1,073 | 610.54 | 812.29 | 378.86 | 373.32 | 61.7 | Upgrade
|
| Gross Profit | 7,247 | 4,495 | 2,070 | 277.65 | 183.93 | 243.99 | Upgrade
|
| Selling, General & Admin | 3,792 | 4,184 | 2,672 | 1,827 | 977.41 | 453.64 | Upgrade
|
| Research & Development | 2,392 | 2,224 | 1,426 | 1,273 | 922.38 | 639.58 | Upgrade
|
| Operating Expenses | 6,185 | 6,408 | 4,098 | 3,100 | 1,900 | 1,093 | Upgrade
|
| Operating Income | 1,063 | -1,913 | -2,028 | -2,822 | -1,716 | -849.22 | Upgrade
|
| Interest Expense | -22.94 | -46.69 | -18.53 | -9.97 | -8.26 | -7.52 | Upgrade
|
| Interest & Investment Income | 922.26 | 585.13 | 40.44 | 4.63 | 7.49 | 8.16 | Upgrade
|
| Currency Exchange Gain (Loss) | -51.65 | 375.7 | 122.36 | -1.85 | 9.82 | -5.3 | Upgrade
|
| Other Non Operating Income (Expenses) | 17.99 | 12.33 | 42.15 | 4.09 | -264.94 | 11.6 | Upgrade
|
| EBT Excluding Unusual Items | 1,928 | -986.93 | -1,842 | -2,826 | -1,972 | -842.29 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.34 | - | -0.1 | -0.07 | 0.02 | 0.14 | Upgrade
|
| Other Unusual Items | - | - | - | 14.59 | 23.71 | - | Upgrade
|
| Pretax Income | 1,928 | -986.93 | -1,842 | -2,811 | -1,948 | -842.14 | Upgrade
|
| Income Tax Expense | 82.03 | -363.1 | -467.06 | - | 0.13 | 0.85 | Upgrade
|
| Net Income | 1,846 | -623.84 | -1,375 | -2,811 | -1,948 | -842.99 | Upgrade
|
| Net Income to Common | 1,846 | -623.84 | -1,375 | -2,811 | -1,948 | -842.99 | Upgrade
|
| Shares Outstanding (Basic) | 331 | 322 | 284 | 260 | 242 | 219 | Upgrade
|
| Shares Outstanding (Diluted) | 333 | 322 | 284 | 260 | 242 | 219 | Upgrade
|
| Shares Change (YoY) | 6.10% | 13.47% | 9.24% | 7.39% | 10.55% | 0.29% | Upgrade
|
| EPS (Basic) | 5.58 | -1.93 | -4.84 | -10.80 | -8.04 | -3.85 | Upgrade
|
| EPS (Diluted) | 5.54 | -1.93 | -4.84 | -10.80 | -8.04 | -3.85 | Upgrade
|
| Free Cash Flow | 437.42 | -1,992 | -1,818 | -2,532 | -1,536 | -1,066 | Upgrade
|
| Free Cash Flow Per Share | 1.31 | -6.18 | -6.40 | -9.73 | -6.34 | -4.86 | Upgrade
|
| Gross Margin | 87.10% | 88.04% | 71.82% | 42.29% | 33.01% | 79.82% | Upgrade
|
| Operating Margin | 12.77% | -37.48% | -70.37% | -429.91% | -307.91% | -277.80% | Upgrade
|
| Profit Margin | 22.19% | -12.22% | -47.70% | -428.17% | -349.59% | -275.77% | Upgrade
|
| Free Cash Flow Margin | 5.26% | -39.01% | -63.06% | -385.74% | -275.72% | -348.64% | Upgrade
|
| EBITDA | 1,171 | -1,824 | -1,912 | -2,703 | -1,621 | -775.32 | Upgrade
|
| EBITDA Margin | 14.08% | -35.73% | -66.34% | - | -290.92% | -253.63% | Upgrade
|
| D&A For EBITDA | 108.89 | 89.24 | 116.28 | 119.59 | 94.7 | 73.9 | Upgrade
|
| EBIT | 1,063 | -1,913 | -2,028 | -2,822 | -1,716 | -849.22 | Upgrade
|
| EBIT Margin | 12.77% | -37.48% | -70.37% | - | - | -277.80% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.